ArticlePloS one2024
Antioxidant, anti-prostate cancer potential, and phytochemical composition of the ethyl acetate stem bark extract of Boascia coriacea (Pax.).
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Solvent-Based Extraction Recovers Phytochemicals from Medicinal Plants Demonstrating Anticancer and Chemopreventive Potential: A Review.Molecules (Basel, Switzerland) · 2026Review
- In vitro cytotoxicity of medicinal plants used in prostate cancer management in Africa: a systematic review.Tropical medicine and health · 2026Review
- Phytochemicals in overcoming venetoclax resistance in acute myeloid leukemia: mechanistic insights and therapeutic potential.Annals of hematology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe antioxidant and anticancer potential of natural compounds, particularly from medicinal plants, is increasingly being explored as alternatives to synthetic antioxidants and chemotherapeutics. Boascia coriacea (Pax) has been traditionally used for treating various ailments, including oxidative stress-related diseases and prostate cancer. However, there is a paucity of empirical evidence to validate the ethnomedicinal claims, hence this study.
methodsThe antioxidant capacity of the extract was assessed using 1,1-Diphenyl-2-picryl Hydrazyl radical (DPPH) radical scavenging and hydrogen peroxide scavenging assays, alongside total antioxidant capacity. In vitro cytotoxicity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on Vero CCL-81 normal cells and DU-145 prostate cancer cells. Gene expression levels of ar, bcl-2, caspase 3, cdk1, and p53 were quantified using qPCR to elucidate the mechanisms of action. Phytochemical analysis was conducted using gas chromatography-mass spectrometry.
resultsThe studied plant extract exhibited significant DPPH radical scavenging activity, with an EC50 of 0.008 μg/ml, 10-fold lower than that of L-ascorbic acid (0.08 μg/ml), indicating potent antioxidant capacity. Similarly, the extract demonstrated substantial hydrogen peroxide scavenging activity, albeit with lower efficacy (EC50 of 1039.10 μg/ml) compared to L-ascorbic acid, and a total antioxidant capacity of 454.39±25.26 μg AAE/mg dw. In vitro cytotoxicity assay revealed a CC50 of 68.61 μg/ml against Vero CCL-81 cells and an IC50 of 32.16 μg/ml against DU-145 cells, with a superior selectivity index of 2.13, compared to doxorubicin's 1.46. The extract significantly downregulated the expression of ar, bcl-2, normalised caspase 3, cdk1 genes while upregulating p53 in DU-145 cells, suggesting its role in inducing apoptosis and inhibiting cancer cell proliferation. Phytochemical analysis identified 19 compounds, including lup-20(29)-en-3-one (7.99%) and lupeol (59.49%), which are associated with anticancer activity.
conclusionThe ethyl acetate stem bark extract of B. coriacea demonstrates significant antioxidant and anticancer activities, potentially through modulation of apoptosis and cell cycle pathways. The presence of bioactive compounds supports its potential as a therapeutic agent, warranting further investigation for developing novel treatments for prostate cancer and oxidative stress-related conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.